In Vivo CRO Market Size Is Projected To Reach USD 7.92 Billion By 2030Posted by Neha Bora on September 7th, 2022 San Francisco, 7 Sep 2022: The Report In Vivo CRO Market Size, Share & Trends Analysis Report By Type (Rodent, Non-Rodent), By GLP Type (Non-GLP, GLP Toxicology), By Indication (Pain Management, Oncology), By Region (North America, APAC), And Segment Forecasts, 2022 - 2030 The global in vivo cro market size is expected to reach USD 7.92 billion by 2030, registering a CAGR of 8.2% according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.5% during the forecast period. Increasing focus on core competencies by the pharmaceutical players coupled with economic efficiency offered for outsourcing is expected to boost the demand. In Addition, the CROs are equipped with a competent workforce capable of performing a diverse number of tasks along with being well-versed through regulatory requirements. Also, the pressure from the increasing competition owing to the rapid growth of generics, patent expirations, and introduction of biosimilar equivalents are encouraging pharmaceutical companies to take the aid of such organizations. Increasing mergers and collaborations have propelled the value of pharmaceutical outsourcing with major industry contributors expanding into developing regions. The year 2015 experienced high valued transactions as a result of LabCorp acquiring Covance for USD 5.5 billion and the Chinese Private Equity Group acquiring WuXifor for USD 3.3 billion. The patent cliff, high research and development cost involved, and globalization in the clinical trial process has driven the Access Research Report of In Vivo CRO Market @ https://www.grandviewresearch.com/industry-analysis/in-vivo-cro-market In Vivo CRO Market Report Highlights
List Of Key Players in the In Vivo CRO Market
Access Press Release of In Vivo CRO Market @ https://www.grandviewresearch.com/press-release/global-in-vivo-cro-market Like it? Share it!More by this author |